Abstract: Tumor growth and metastasis can be inhibited by administration of adenosine A1 and/or A3 antagonists, preferably A3 antagonists, to a patient. The antagonists can be, and preferably are, administered in combination with other anti-tumor agents, such as anti-angiogenic agents (including adenosine A2a antagonists) and/or cytotoxic agents. Because the cytotoxic agents attack the tumor cells themselves, and the anti-angiogenic agents prevent the growth of vasculature which would otherwise support the growth of the tumor cells.
Type:
Grant
Filed:
August 19, 1999
Date of Patent:
December 4, 2001
Assignee:
King Pharmaceuticals Reseach and Development, Inc.
Inventors:
Edward Leung, Pier Giovanni Baraldi, Pier Andrea Borea, Shih-Fong Chen